July 8, 2026 · BMJ (Clinical research ed.) · DOI: 10.1136/bmj-2025-085211

Advances in systemic therapies for advanced prostate cancer

Listen to this summary

The authors aim to review recent advancements in the systemic therapies for advanced prostate cancer, particularly focusing on high-risk biochemical recurrence, metastatic hormone-sensitive prostate cancer (mHSPC), and metastatic castration-resistant prostate cancer (mCRPC). They highlight the impact of early use of androgen receptor pathway inhibitors, the role of advanced imaging and genomic biomarkers for personalized treatment, and the evolving landscape of treatment options, including chemotherapy and PARP inhibitors, while also addressing the management of adverse effects as patient survival improves.

Daniel S Childs, Andrew W Hahn, Praful Ravi, Jacob J Orme

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play